Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848947 · ClinicalTrials.gov registry record · Phase 4
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
A Phase 4 study, sponsored by Sirtex Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT05848947: Completed Phase 4 study, sponsored by Sirtex Medical.
NCT05848947 is a Phase 4 study that has completed, run by Sirtex Medical. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05848947, a Phase 4 study, has completed, sponsored by Sirtex Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.
Interventions
- DRUG 99mTc-Macro Albumin Aggregate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-07-05 |
| Phase | Phase 4 |
What the finished NCT05848947 record still lists
NCT05848947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which 99mTc-Macro Albumin Aggregate is the first listed.
NCT05848947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05848947 about?
NCT05848947 is a clinical study titled "SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA". The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatoce...
What is the current status of trial NCT05848947?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2023-04-25. Estimated completion is 2023-07-05.
What interventions are being tested in trial NCT05848947?
The interventions under investigation include: 99mTc-Macro Albumin Aggregate (DRUG).
Who is sponsoring clinical trial NCT05848947?
This trial is sponsored by Sirtex Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05848947's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI